NEW YORK, June 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:Carisma Therapeutics Inc. (NASDAQ: CARM)'s merger with OrthoCellix, Inc. Upon completion of the proposed transaction, existing Carisma shareholders are expected to own approximately 10% of the combined company. If you are a Carisma shareholder, click here to learn ...

Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseasesOrthoCellix is developing the Phase 3-ready NeoCart® as an autologous cartilage implant technology utilizing patient cells to repair articular cartilage defects of the knee PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________to _________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-K ____________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________to ___ ...

Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn Pipeline Updates Fibrosis Ex Vivo Oncology In Vivo Program (Moderna Collaboration) Our liver fibrosis program is based upon the discovery of a key efferocytosis defect in the macrophages that reside within the livers of patients with fibrosis. Using a novel mRNA/LNP approach, our product candidate, CT-2401, aims to reverse fibrotic disease and improve the outcomes of patients with advance ...

PHILADELPHIA, Feb. 19, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET.An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be ...

PHILADELPHIA, Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11 at 4:40 pm ET. An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limite ...

New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis modelsEngineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity PHILADELPHIA, Nov. 17, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today presented promising preclinical data on engin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________to _____ ...

Financial Performance - The net loss for Q3 2024 was $12.7 million, compared to a net loss of $21.4 million for the same period in 2023[12]. - Net loss for September 2024 was $(12,702,000), compared to $(21,403,000) in September 2023, indicating a reduction of approximately 40.5%[20]. - The operating loss improved from $(22,344,000) in September 2023 to $(13,144,000) in September 2024, reflecting a decrease in loss of about 41.2%[20]. - The net loss per share improved from $(0.53) in September 2023 to $(0.31) in September 2024, indicating a positive trend in per-share loss[20]. Cash and Assets - Carisma Therapeutics reported cash and cash equivalents of $26.9 million as of September 30, 2024, down from $40.4 million as of June 30, 2024[9]. - Cash and cash equivalents decreased significantly from $77,605,000 on December 31, 2023, to $26,881,000 on September 30, 2024, a drop of about 65.4%[19]. - Total current assets decreased from $80,471,000 on December 31, 2023, to $34,137,000 on September 30, 2024, a decline of approximately 57.6%[19]. - Total liabilities decreased from $63,022,000 on December 31, 2023, to $53,184,000 on September 30, 2024, a decline of approximately 15.6%[19]. - The accumulated deficit increased from $(245,102,000) on December 31, 2023, to $(287,944,000) on September 30, 2024, reflecting an increase of about 17.5%[19]. Research and Development - Research and development expenses for Q3 2024 were $11.3 million, a decrease of $8.3 million compared to $19.6 million in Q3 2023, primarily due to a revised operating plan[10]. - Initial results from the Phase 1 study of CT-0525 are expected in the first quarter of 2025[1]. - A development candidate for the liver fibrosis program is anticipated to be nominated in the first quarter of 2025[1]. - New preclinical efficacy data for anti-GPC3 in vivo CAR-M therapy will be presented on November 8, 2024, at the SITC Annual Meeting[1]. - The Phase 1 study of CT-0525 includes a protocol amendment allowing for repeat dosing of up to 2 billion CAR positive cells every three weeks[3]. Collaboration and Revenue - Carisma has expanded its collaboration with Moderna to include two research targets for autoimmune diseases[5]. - Collaboration revenues for September 2024 were $3,385,000, down from $3,827,000 in September 2023, representing a decrease of about 11.6%[20]. Operating Expenses - General and administrative expenses for Q3 2024 were $5.2 million, down from $6.6 million in Q3 2023, reflecting a $1.4 million decrease[11]. - Total operating expenses decreased from $26,171,000 in September 2023 to $16,529,000 in September 2024, a reduction of approximately 36.9%[20]. - The company expects to sustain its operations into the third quarter of 2025 with the current cash position[13].